- Home
- / NeuroPace
NeuroPace
Stock Price
$6.5
2024-10-29
Market Capitalization
$189.5 M
2024-10-29
Revenue
$100 M
FY, 2025
NeuroPace Summary
Company Summary
- Overview
- NeuroPace is a company that designs, develops, and manufactures implantable devices for the treatment of neurological disorders. It develops the RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy.
- Type
- Public
- Status
- Active
- Founded
- 1997
- HQ
- Mountain View, CA, US | view all locations
- Website
- https://neuropace.com
- Cybersecurity rating
- Sectors
Table of Contents
Key People
Martha Morrell, Chief Medical Officer
Patrick F. Williams, Chief Financial Officer
Chris Reese, Senior Vice President of Sales
Operating MetricsView all
Patents Issued
132
FY, 2020
Patients Treated
3K
FY, 2020
Patent Applications (US)
14
FY, 2020
LocationsView all
1 location detected
Mountain View, CA HQ
United States
455 N. Bernardo Avenue
NeuroPace Financials
Summary Financials
- Revenue (FY, 2025)
- $100.0M
- Gross profit (FY, 2025)
- $77.2M
- Net income (FY, 2025)
- ($21.5M)
- Cash (FY, 2025)
- $21.7M
- EBIT (FY, 2025)
- ($16.3M)
- Enterprise value
- $250.6M